Christopher M. Gallagher, MD, discusses unmet needs surrounding the use of antibody-drug conjugates, as well as questions remaining with other approved agents in breast cancer.
Christopher M. Gallagher, MD
Advertisement
Articles by Christopher M. Gallagher, MD
Christopher M. Gallagher, MD, discusses treatment sequencing considerations with antibody-drug conjugates in patients with HER2-low metastatic breast cancer.
Advertisement
Latest Updated Articles
Dr Gallagher on Unmet Needs With ADCs in Breast CancerDecember 1st 2023
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5